article thumbnail

New Data for Medtronic CoreValve/Evolut TAVR Systems Reinforces Excellent Valve Performance

DAIC

milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aortic valve replacement (TAVR) System compared to surgical aortic valve replacement (SAVR) and other TAVR valves. Evolut vs. 10.6%

TAVR 111
article thumbnail

Medtronic Announces FDA Approval of Newest-generation Evolut TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

DAIC

milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.

TAVR 111
article thumbnail

Almost 50% of Patients Under 60 Years Choose TAVR Over Surgical Aortic Valve Replacement with Worse Outcomes

DAIC

From a pool of 37,011 patients, the study identified 2,360 patients under the age of 60 years who underwent these procedures, with 22% receiving TAVR and 78% SAVR. By 2021 almost half of patients younger than 60 years were receiving TAVR rather than SAVR. years after TAVR and 4.9 years after TAVR and 4.9

article thumbnail

Edwards Acquires JenaValve and Endotronix, Expands into Aortic Regurgitation and Heart Failure

CardiacWire

Edwards Lifesciences is going all-in on structural heart and heart failure, acquiring aortic valve-maker JenaValve Technology and implantable heart failure monitor company Endotronix for $1.2B and up to $445M in milestone payments.

article thumbnail

Top 10: What Viewers Were Reading in March

DAIC

CLS Health Cardiologists Achieve Historic First with Transcarotid TAVR in Southeast Houston 2. New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform 5. Boston Scientific Receives FDA Approval for the AGENT Drug-Coated Balloon 4.

TAVR 105
article thumbnail

Does TAVR Benefit Patients with Moderate Aortic Stenosis and Systolic Heart Failure?

NEJM Journal Watch - Cardiology

A small randomized study failed to show a benefit of TAVR in this population.

TAVR 40
article thumbnail

Severe Aortic Stenosis, Titration and Acute Heart Failure, Pacemakers After TAVR

American College of Cardiology

He then examines titration of medications after acute heart failure. In this week's View, Dr. Eagle looks at secular trends of incidence and outcomes in severe aortic stenosis.